Skip to main content

22 November 2024

Last updated: Friday 22 November 2024

User account anon menu

Login
Register and subscribe

Search

Home
News
About MedNous
Research Directory
Contact Us
- Contact Form

Menu

Breadcrumb

Home
Developing Radionuclide PARP Inhibitors

Developing radionuclide PARP inhibitors

Sunday 22 November 2020

Interviewee/Contributor

Greg Mullen

Organisation

Theragnostics Ltd

---Subscribe to MedNous to access this article---

Cancer (Oncology)

Personalised medicine

Select a News Category

Clinical Research
Company News
Finance, Grants, Deals
IPR & Legal
Regenerative Medicine
Regulation & Policy
Research & University News

Recent Appointments

Calluna Pharma appoints new CEO and board chair

Tuesday 22 October 2024

New CFO at Cosmo Pharmaceuticals

Tuesday 22 October 2024

New CEO at Oncovita

Tuesday 22 October 2024

Abalos Therapeutics appoints new CEO

Tuesday 22 October 2024

Innate Pharma names Jonathan Dickinson as CEO

Tuesday 22 October 2024

View more appointments

Looking for more?

MedNous covers medical news and more. See more in our various site sections.

News
Industry appointments
Events
Research directory
Subscribe

Footer

Privacy policy

© 2024 Evernow Publishing Ltd.

Home
News
- News
- Appointments
- Events
About MedNous
Research Directory
Contact Us
- Contact Form